Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapy

被引：3

作者：

Weinstock, Matt ^{[1
]}

Elavalakanar, Pavania ^{[1
]}

Bright, Susan ^{[1
]}

Ambati, Srikanth R. ^{[2
]}

Brouwer-Visser, Jurriaan ^{[2
]}

Pourpe, Stephane ^{[2
]}

Fiaschi, Nathalie ^{[2
]}

Jankovic, Vladimir ^{[2
]}

Thurston, Gavin ^{[2
]}

Deering, Raquel P. ^{[2
]}

Chaudhry, Aafia ^{[2
]}

Joyce, Robin ^{[1
]}

Arnason, Jon ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Hematol Oncol, Boston, MA 02215 USA

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 199卷 / 03期

关键词：

bispecific antibodies; cellular therapies; clinical trials; non-Hodgkin lymphoma; tumour immunotherapy;

D O I：

10.1111/bjh.18383

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 x CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for >= 2 years following odronextamab. Neither patient experienced Grade >= 3 cytokine release syndrome or Grade >= 3 neurological adverse events during treatment.

引用

页码：366 / 370

页数：5

共 50 条

[21] PAYER AND PRESCRIBER PERSPECTIVES ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES IN DIFFUSE LARGE B-CELL LYMPHOMA
Privolnev, Y.
Vinuesa, L.
VALUE IN HEALTH, 2019, 22 : S425 - S425
[22] Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma
Wang, Tao
Gao, Lei
Wang, Yujie
Zhu, Wenjun
Xu, Lili
Wang, Yang
Yue, Wenqin
Tang, Gusheng
Chen, Li
Chen, Jie
Zhang, Weiping
Yu, Xuejun
Feng, Dongge
Yang, Jianmin
IMMUNOTHERAPY, 2020, 12 (13) : 997 - 1006
[23] Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy
Dang, Xiuyong
Ye, Shiguang
Zhou, Lili
Lu, Yan
Li, Ping
Liang, Aibin
Qian, Wenbin
CYTOTHERAPY, 2023, 25 (06) : 573 - 577
[24] Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
Sophie Snyder
Karen C. Chung
Monika P. Jun
Matthew Gitlin
Advances in Therapy, 2021, 38 : 4659 - 4674
[25] Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
Lyman, Gary H.
Nguyen, Andy
Snyder, Sophie
Gitlin, Matthew
Chung, Karen C.
JAMA NETWORK OPEN, 2020, 3 (04) : E202072
[26] Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy
Jallouk, Andrew P.
Kui, Naishu
Sun, Ryan
Westin, Jason R.
Steiner, Raphael E.
Nair, Ranjit
Nastoupil, Loretta J.
Fayad, Luis E.
Al Zaki, Ajlan
Hawkins, Misha
Adkins, Sherry
Noorani, Mansoor
Das, Kaberi
Henderson, Jared
Shpall, Elizabeth J.
Kebriaei, Partow
Ramdial, Jeremy
Flowers, Christopher R.
Neelapu, Sattva S.
Ahmed, Sairah
Strati, Paolo
HAEMATOLOGICA, 2024, 109 (05) : 1460 - 1468
[27] Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
Snyder, Sophie
Chung, Karen C.
Jun, Monika P.
Gitlin, Matthew
ADVANCES IN THERAPY, 2021, 38 (09) : 4659 - 4674
[28] Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy
Iacoboni, Gloria
Iraola-Truchuelo, Josu
O'Reilly, Maeve
Navarro, Victor
Menne, Tobias
Kwon, Mi
Martin-Lopez, Ana africa
Chaganti, Sridhar
Delgado, Javier
Roddie, Claire
Perez, Ariadna
Norman, Jane
Guerreiro, Manuel
Gibb, Adam
Caballero, Ana Carolina
Besley, Caroline
Martinez-Cibrian, Nuria
Mussetti, Alberto
Sanderson, Robin
Luzardo, Hugo
Iyengar, Sunil
Sanchez, Jose Maria
Jones, Ceri
Sancho, Juan-Manuel
Barba, Pere
Latif, Anne-Louise
Lopez-Corral, Lucia
Hernani, Rafael
Reguera, Juan Luis
Sureda, Anna
Garcia-Sancho, Alejandro Martin
Bastos, Mariana
Abrisqueta, Pau
Kuhnl, Andrea
HEMASPHERE, 2024, 8 (05):
[29] Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
Hoffmann, Marc S.
Hunter, Bradley D.
Cobb, Patrick W.
Varela, Juan C.
Munoz, Javier
TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (07): : 440 - 448
[30] Salvage Radiation Treatment for Primary Refractory Diffuse Large B-cell Lymphoma After Chimeric Antigen Receptor (CAR) T-cell Therapy: A Case Report
Wang, Kaidi
Prabhu, Arpan V.
Sasapu, Appalanaidu
Lewis, Gary D.
ANTICANCER RESEARCH, 2021, 41 (07) : 3635 - 3638

← 1 2 3 4 5 →